Opiant Pharmaceuticals Inc (NASDAQ:OPNT) insider Phil Skolnick sold 7,143 shares of the stock in a transaction dated Tuesday, December 3rd. The stock was sold at an average price of $13.47, for a total transaction of $96,216.21.
Phil Skolnick also recently made the following trade(s):
- On Tuesday, November 5th, Phil Skolnick sold 10,000 shares of Opiant Pharmaceuticals stock. The shares were sold at an average price of $15.80, for a total transaction of $158,000.00.
- On Thursday, October 3rd, Phil Skolnick sold 10,000 shares of Opiant Pharmaceuticals stock. The stock was sold at an average price of $14.68, for a total transaction of $146,800.00.
OPNT stock traded up $0.11 during midday trading on Friday, reaching $13.87. The stock had a trading volume of 4,181 shares, compared to its average volume of 20,627. The firm has a market cap of $57.00 million, a price-to-earnings ratio of -1.95 and a beta of 0.25. Opiant Pharmaceuticals Inc has a twelve month low of $9.98 and a twelve month high of $18.23. The company has a quick ratio of 4.28, a current ratio of 4.28 and a debt-to-equity ratio of 0.01. The business has a fifty day simple moving average of $14.74 and a two-hundred day simple moving average of $13.83.
Opiant Pharmaceuticals (NASDAQ:OPNT) last issued its earnings results on Tuesday, November 12th. The technology company reported $1.97 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.10 by $1.87. Opiant Pharmaceuticals had a net margin of 24.16% and a negative return on equity of 7.39%. The company had revenue of $20.64 million for the quarter, compared to analyst estimates of $5.73 million. On average, equities analysts predict that Opiant Pharmaceuticals Inc will post 0.23 earnings per share for the current fiscal year.
Several research firms have recently commented on OPNT. TheStreet raised shares of Opiant Pharmaceuticals from a “d” rating to a “c-” rating in a research note on Friday, August 30th. Northland Securities restated a “buy” rating and set a $42.00 target price on shares of Opiant Pharmaceuticals in a research report on Thursday, November 7th.
Hedge funds and other institutional investors have recently made changes to their positions in the stock. BlackRock Inc. boosted its stake in Opiant Pharmaceuticals by 93.5% in the second quarter. BlackRock Inc. now owns 20,792 shares of the technology company’s stock valued at $276,000 after acquiring an additional 10,045 shares during the last quarter. Wedge Capital Management L L P NC acquired a new stake in Opiant Pharmaceuticals during the 3rd quarter worth $363,000. Advisor Group Inc. grew its holdings in Opiant Pharmaceuticals by 24.3% during the 2nd quarter. Advisor Group Inc. now owns 4,600 shares of the technology company’s stock worth $61,000 after acquiring an additional 900 shares during the period. Morgan Stanley raised its position in shares of Opiant Pharmaceuticals by 1,000.3% during the 2nd quarter. Morgan Stanley now owns 22,414 shares of the technology company’s stock valued at $297,000 after acquiring an additional 20,377 shares during the last quarter. Finally, Stonepine Capital Management LLC raised its position in shares of Opiant Pharmaceuticals by 7.0% during the 2nd quarter. Stonepine Capital Management LLC now owns 315,468 shares of the technology company’s stock valued at $4,180,000 after acquiring an additional 20,574 shares during the last quarter. Institutional investors and hedge funds own 21.49% of the company’s stock.
Opiant Pharmaceuticals Company Profile
Opiant Pharmaceuticals, Inc, a specialty pharmaceutical company, develops pharmacological treatments for substance use, addictive and eating disorders. The company offers NARCAN nasal spray, a treatment to reverse opioid overdoses. Its pipeline of product candidates includes treatments for eating disorders, including bulimia nervosa and binge eating disorders, alcohol use disorders, a long term treatment to prevent relapse for patients with opioid use disorders, cocaine use disorders, and a heroin vaccine.
Featured Story: Convertible Shares
Receive News & Ratings for Opiant Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opiant Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.